Product
CMAB807
Aliases
CMAB807 Injection, Denosumab Injection
Name
Prolia
INN Name
denosumab
FDA Approved
Yes
2 clinical trials
1 organization
2 indications
2 documents
Indication
OsteoporosisIndication
Healthy Control ParticipantsClinical trial
Randomized, Doubel-blinded, Parallel, Active-controlled Phase III Study, to Evaluate the Efficacy and Safety of CMAB807 Treatment Compared With Prolia® in Chinese Postmenopausal Women With Osteoporosis at High Risk of Fracture.Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Randomized, Double-blind, Parallel Controlled, Phase I Study, Comparing the PK, PD, Safety, and Immunogenicity of Post-change CMAB807and Prolia in Healthy Chinese SubjectsStatus: Recruiting, Estimated PCD: 2024-05-30
Document
DailyMed Label: ProliaOrganization
Amgen IncDocument
DailyMed Label: XGEVA